Studies on AD have shown that PKC activation has a positive impact on amyloid pathology, enhancing the secretion of the α-secretase product sAPPα and reducing Aβ40 (Etcheberrigaray et al., 2004) and tau pathology (Isagawa et al., 2000). Here, PRRT2 is linked to Alzheimer disease.